StockData

Xilio Therapeutics vs Xencor

XLO and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How XLO and XNCR compare

Xencor is the larger company, worth 59 times as much as Xilio Therapeutics ($2.6B against $43.6M).

Xilio Therapeutics grew revenue faster over the last twelve months (327% versus −28.6% for Xencor).

Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −156% at Xencor.

Xilio Therapeutics scores higher on the StockData Score (11 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricXLOXNCR
Size and price
Market cap$43.6M$2.6B
Share price$7.54$34.50
Change, 1 year−23.8%131%
Change, 5 years−97.3%−2.7%
Beta (5Y)0.03−0.05
Employees76260
StockData Score
Total score11 (better)5
Valuation score3 (better)0
Growth score11
Performance score2 (better)1
Health score5 (better)3
Dividend score00
Valuation
P/S0.7× (better)24.4×
P/B0.6× (better)5.1×
FCF yield−141%−8.1% (better)
Fair value$37.97$11.73
Margin of safety80.1% (better)−194%
Growth
Revenue growth (TTM)327% (better)−28.6%
Revenue growth, 5Y average–0.47%
Profitability
Operating margin−48.9% (better)−206%
Net margin−34.1% (better)−156%
FCF margin−95.6% (better)−198%
Return on equity−55.0%−29.1% (better)
Return on invested capital–−26.6%
Financial health
Debt / equity0.000.21 (better)
Interest coverage–−8.0×
Current ratio4.256.39 (better)
Altman Z-score−3.025.01 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions58.9%113%
Held by insiders–1.6%
Insider net buying, 12 months$38.3K (better)−$7.5M
Short interest, % of float–17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.